A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

NCT00423202 | Completed Phase 3

• 2 other identifiers: AMB-321ARIES-2
• Study Type: interventional
• Target: 186
• Locations: 0 countries
• Sites: N/A

Brief Summary

A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.

Conditions

Pulmonary Arterial Hypertension

Outcome Measures

Primary Outcomes (1)

• Change from baseline in the six-minute walk distance evaluated after 12 weeks of therapy compared to placebo.

Secondary Outcomes (3)

• Change from baseline measured after 12 weeks of treatment compared to placebo in the Borg Dyspnea Index immediately following exercise, WHO functional class and SF-36 Health Survey.

• Clinical worsening of PAH.

• Assessment of the safety and tolerability of the study drug.

Interventions

ambrisentan DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years of age and older
• Current diagnosis of either PPH or PAH secondary to the scleroderma spectrum of disease, systemic lupus erythematosus, anorexigen use, or HIV infection at the Screening Visit
• Right heart catheterization, completed prior to Screening Visit must meet pre-specified hemodynamic criteria
• Female subjects of childbearing potential must have a negative serum pregnancy test and must agree to use a reliable double barrier method of contraception until study completion and for at least four weeks following their final study visit
• Male subjects must be informed of the potential risks of testicular tubular atrophy and infertility associated with taking this study drug and queried regarding his understanding of the potential risks as described in the Informed Consent Form

You may not qualify if:

• PAH due to or associated with congenital heart disease, coronary artery disease, left heart disease, interstitial lung disease, chronic obstructive pulmonary disease, veno-occlusive disease, chronic thrombotic and/or embolic disease, or sleep apnea
• Portopulmonary hypertension
• Bosentan within four weeks prior to Screening
• Phosphodiesterase type V inhibitor or chronic prostanoid therapy within four weeks prior to Screening
• IV inotrope use within two weeks prior to Screening
• ALT or AST lab value that is greater than 1.5 times the upper limit of normal
• Pulmonary function tests not meeting pre-specified criteria
• Contraindication to treatment with an ERA
• History of malignancies other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the past five years
• Females who are pregnant or breastfeeding

Sponsors & Collaborators

• Gilead Sciences: lead

MeSH Terms

Conditions

Pulmonary Arterial Hypertension

Interventions

ambrisentan

Condition Hierarchy (Ancestors)

Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: January 17, 2007
• First Posted: January 18, 2007
• Study Start: December 1, 2003
• Study Completion: October 1, 2005
• Last Updated: April 16, 2009

Record last verified: 2009-04